Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Gestational choriocarcinoma, chorioadenoma destruens; hydatidiform mole; acute lymphocytic leukemia; meningeal leukemia; breast cancer; epidermoid cancers of the head and neck; advanced mycosis fungoides; lung cancer, particularly squamous cell and small cell types; non-Hodgkin's lymphomas; non-metastatic osteosarcoma; severe, recalcitrant, disabling psoriasis; severe, active, classical or definite rheumatoid arthritis unresponsive to conventional therapy.
Orally or IM, 15-30 mg daily x 5/7. This is repeated for 3-5 times with rest periods of at least one week interjected between courses, until any manifesting toxic symptoms subside. Consult specialist literature for further information.
Ulcerative stomatitis; leukopenia; nausea; anorexia; vomiting; abdominal distress; malaise; asthenia; chills and fever; dizziness; decreased resistance to infection; gingivitis; pharyngitis; diarrhoea; hematemesis; melena; GI ulceration and bleeding; enteritis; transient subtle cognitive dysfunction; mood alteration; unusual cranial sensations; headache; drowsiness; blurred vision; interstitial pneumonitis; erythematous rashes, pruritus; urticaria; photosensitivity; pigmentary changes; alopecia; ecchymosis; telangiectasia; acne; furunculosis.
Store as labelled. Keep out of reach of children.